Cargando…
Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action
BACKGROUND: Health technology assessment (HTA) agencies have an important role in the evaluation and approval of new technologies. They determine their value within a health system so to promote equitable, quality care with available healthcare resources. Many HTA agencies have some mechanism for in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783693/ https://www.ncbi.nlm.nih.gov/pubmed/33402216 http://dx.doi.org/10.1186/s40900-020-00248-9 |
_version_ | 1783632160895270912 |
---|---|
author | Wale, Janet L. Thomas, Samuel Hamerlijnck, Dominique Hollander, Ronald |
author_facet | Wale, Janet L. Thomas, Samuel Hamerlijnck, Dominique Hollander, Ronald |
author_sort | Wale, Janet L. |
collection | PubMed |
description | BACKGROUND: Health technology assessment (HTA) agencies have an important role in the evaluation and approval of new technologies. They determine their value within a health system so to promote equitable, quality care with available healthcare resources. Many HTA agencies have some mechanism for involving patients in their processes, but there is great variability and an absence of comprehensive, robust practices for involvement. The accelerating pace of medical innovation creates a need to improve the depth and breadth of patient involvement in the HTA process. MAIN BODY: In this ‘Call to action’, we present ideas from three HTA expert commentaries calling for collaborative learning and to share innovative ideas for changes in HTA. We also draw on examples of HTA agencies creatively pursuing this goal. We propose a ‘Call to action’ for HTA stakeholders to undertake serious dialogue with patient advocates aimed at creating shared goals. HTA agencies can use these goals to ensure meaningful patient involvement at every step of the HTA process. Five elements are explored. In ‘Recognizing the value of shared purpose’, we highlight examples of HTA agencies that have patients working in partnership with medical practitioners and HTA staff. Results include improved processes that instil confidence. ‘Committing to patient involvement as part of HTA culture’ highlights several initiatives aimed at changes in HTA organisational culture to be more inclusive of patients. In ‘Aligning patient and HTA goals’ we cite work in Belgium and New Zealand which places a greater emphasis on quality of life rather than life expectancy and cost-effectiveness. By ‘Integrating patient involvement at every step of the HTA process’ patients can make vital contributions at every stage of the HTA process. We provide two examples of where HTA agencies have successfully involved patients early in the process in order to broaden the scope of evaluations. ‘Developing a common language and working together’ can support transformative dialogue through ‘unified language’. CONCLUSION: The authors of this commentary ask that agencies and stakeholders involved in HTA take up this call to work together for visionary and transformative elevation of the voice of patients in HTA worldwide. |
format | Online Article Text |
id | pubmed-7783693 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-77836932021-01-05 Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action Wale, Janet L. Thomas, Samuel Hamerlijnck, Dominique Hollander, Ronald Res Involv Engagem Commentary BACKGROUND: Health technology assessment (HTA) agencies have an important role in the evaluation and approval of new technologies. They determine their value within a health system so to promote equitable, quality care with available healthcare resources. Many HTA agencies have some mechanism for involving patients in their processes, but there is great variability and an absence of comprehensive, robust practices for involvement. The accelerating pace of medical innovation creates a need to improve the depth and breadth of patient involvement in the HTA process. MAIN BODY: In this ‘Call to action’, we present ideas from three HTA expert commentaries calling for collaborative learning and to share innovative ideas for changes in HTA. We also draw on examples of HTA agencies creatively pursuing this goal. We propose a ‘Call to action’ for HTA stakeholders to undertake serious dialogue with patient advocates aimed at creating shared goals. HTA agencies can use these goals to ensure meaningful patient involvement at every step of the HTA process. Five elements are explored. In ‘Recognizing the value of shared purpose’, we highlight examples of HTA agencies that have patients working in partnership with medical practitioners and HTA staff. Results include improved processes that instil confidence. ‘Committing to patient involvement as part of HTA culture’ highlights several initiatives aimed at changes in HTA organisational culture to be more inclusive of patients. In ‘Aligning patient and HTA goals’ we cite work in Belgium and New Zealand which places a greater emphasis on quality of life rather than life expectancy and cost-effectiveness. By ‘Integrating patient involvement at every step of the HTA process’ patients can make vital contributions at every stage of the HTA process. We provide two examples of where HTA agencies have successfully involved patients early in the process in order to broaden the scope of evaluations. ‘Developing a common language and working together’ can support transformative dialogue through ‘unified language’. CONCLUSION: The authors of this commentary ask that agencies and stakeholders involved in HTA take up this call to work together for visionary and transformative elevation of the voice of patients in HTA worldwide. BioMed Central 2021-01-05 /pmc/articles/PMC7783693/ /pubmed/33402216 http://dx.doi.org/10.1186/s40900-020-00248-9 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Commentary Wale, Janet L. Thomas, Samuel Hamerlijnck, Dominique Hollander, Ronald Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action |
title | Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action |
title_full | Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action |
title_fullStr | Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action |
title_full_unstemmed | Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action |
title_short | Patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action |
title_sort | patients and public are important stakeholders in health technology assessment but the level of involvement is low – a call to action |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783693/ https://www.ncbi.nlm.nih.gov/pubmed/33402216 http://dx.doi.org/10.1186/s40900-020-00248-9 |
work_keys_str_mv | AT walejanetl patientsandpublicareimportantstakeholdersinhealthtechnologyassessmentbutthelevelofinvolvementislowacalltoaction AT thomassamuel patientsandpublicareimportantstakeholdersinhealthtechnologyassessmentbutthelevelofinvolvementislowacalltoaction AT hamerlijnckdominique patientsandpublicareimportantstakeholdersinhealthtechnologyassessmentbutthelevelofinvolvementislowacalltoaction AT hollanderronald patientsandpublicareimportantstakeholdersinhealthtechnologyassessmentbutthelevelofinvolvementislowacalltoaction |